Kosovo’s Ozempic Craze Sparks Health Alarms as Demand Soars
In Kosovo, the diabetes medication Ozempic has become a popular weight-loss solution, despite serious health warnings and regulatory concerns. Originally approved for type 2 diabetes management, Ozempic is now widely used off-label for slimming purposes, often without medical supervision.
Influencer Tringa Kadriu, 29, exemplifies this trend, aiming to shed 15–16 kilograms in two months using Ozempic, followed by fitness routines. She notes the drug’s easy availability in pharmacies, even without a prescription, and reports that pharmacists sometimes advise on dosage increases.
The drug’s popularity has led to a price surge, with monthly doses rising from €75–80 to €130–140. Despite its appetite-suppressing effects, health professionals warn of potential side effects, including thyroid cancer, pancreatitis, gastroparesis, and bowel obstruction. Dr. Merita Emini-Sadiku, head of the endocrinology clinic at Kosovo’s university hospital, emphasizes the risks associated with unsupervised use.
Regulatory bodies face challenges in controlling Ozempic’s distribution, with only 20 pharmaceutical inspectors overseeing approximately 1,500–1,600 private pharmacies. Journalist Bujar Vitija highlights the lack of comprehensive health data, complicating enforcement efforts.
As over 57% of Kosovo’s population is overweight, the allure of a quick weight-loss solution like Ozempic is strong. However, health experts urge caution, stressing the importance of medical guidance and awareness of potential health risks.
2026-08-31
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
EAEU Initiates Review of Anti-Dumping Measures on Chinese Titanium Dioxide, Suspends Duties During Investigation
-
FDA Tracks Industry Dye Removal
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
G20 Pushes Fertilizer Access as Food-Security Risk Rises
-
India Prepares New Seed and Pesticide Laws
-
Syngenta Caught in Trade Crossfire
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
Recommend Reading
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
FDA and NIH Launch a New Nutrition Science Partnership
-
FDA Sharpens the Dietary Supplement Ingredient Debate
-
FDA Reopens the Raw Manure Debate
-
Premium Global Chemical Sourcing Requests (13-16Aug, 2026)
-
Cost Advantages Support, Polyester Staple Fiber Prices Remain on an Upward Trend
-
Crude oil remains in negative territory, another round of retail fuel price cuts in China
-
Recent Low-Range Fluctuations in Dichloromethane
-
Potassium Hydroxide (KOH): Soap Making, Batteries, and Safety